DOYLESTOWN, Pennsylvania, March 25, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. PRPH www.ProPhaseLabs.com))) today announced its net sales were $9.9 million for the year ended December 31, 2019, as compared to net sales of $13.1 million for the year ended December 31, 2018.
The Company incurred a net loss from continuing operations for the year ended December 31, 2019 of $3.1 million, or ($0.27) per share, as compared to a loss of $1.6 million, or ($0.14) per share, for the year ended December 31, 2018. The Company incurred loss from discontinued operations for the year ended December 31, 2019 of $40,000, or ($0.00) per share, as compared to loss of $170,000, or ($0.01) per share, for the year ended December 31, 2018. The Company incurred net loss for the year ended December 31, 2019, of $3.1 million, or ($0.27) per share, as compared to a loss of $1.7 million, or ($0.15) per share, for the year ended December 31, 2018.
The financial results for the year ended December 31, 2019 as compared to the year ended December 31, 2018 principally reflect the net effect of (i) a decrease in net sales of $3.2 million principally due to a decrease in demand of third party customer orders, (ii) a decrease in administration costs of $430,000 due principally to a decrease in professional and legal costs, (iii) a decrease in sales and marketing expenses of $65,000 as a consequence of a reduction in marketing initiatives and (iv) a decrease in research and development expenditures of $66,000.
About the Company
We are a manufacturing and marketing company with deep experience with OTC consumer healthcare products and dietary supplements. We are engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States. This includes the development and marketing of dietary supplements under the TK Supplements® brand.
In addition, the Company also continues to actively pursue acquisition opportunities for other companies, technologies and products inside and outside the consumer products industry. For more information visit us at www.ProPhaseLabs.com.
Forward Looking Statements
Except for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to potential acquisition opportunities. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include, but are not limited to: the difficulty of predicting the acceptance and demand for our products, the impact of competitive products and pricing, costs involved in the manufacture and marketing of products, the timely development and launch of new products, and the risk factors listed from time to time in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any subsequent SEC filings.
Investor Contact
Ted Karkus, Chairman and CEO
ProPhase Labs, Inc.
(267) 880-1111
ProPhase Labs, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
| For the Years Ended | ||||||||
| December 31, 2019 | December 31, 2018 | |||||||
| Net sales | $ | 9,876 | $ | 13,126 | ||||
| Cost of sales | 7,261 | 8,345 | ||||||
| Gross profit | 2,615 | 4,781 | ||||||
| Operating expenses: | ||||||||
| Sales and marketing | 1,042 | 1,107 | ||||||
| Administration | 4,480 | 4,910 | ||||||
| Research and development | 332 | 398 | ||||||
| Total operating expenses | 5,854 | 6,415 | ||||||
| Loss from operations | (3,239 | ) | (1,634 | ) | ||||
| Interest income, net | 133 | 167 | ||||||
| Loss from continuing operations before income taxes | (3,106 | ) | (1,467 | ) | ||||
| Income tax liability from continuing operations | - | (103 | ) | |||||
| Loss from continuing operations | (3,106 | ) | (1,570 | ) | ||||
| Discontinued operations: | ||||||||
| Loss on discontinued operations, net of taxes | (40 | ) | (170 | ) | ||||
| Loss from discontinued operations | (40 | ) | (170 | ) | ||||
| Net loss | $ | (3,146 | ) | $ | (1,740 | ) | ||
| Other comprehensive income (loss): | ||||||||
| Unrealized gain on marketable debt securities | 22 | 54 | ||||||
| Total comprehensive loss | $ | (3,124 | ) | $ | (1,686 | ) | ||
| Basic and diluted loss per share: | ||||||||
| Loss from continuing operations | $ | (0.27 | ) | $ | (0.14 | ) | ||
| Loss from discontinued operations | - | (0.01 | ) | |||||
| Net loss | $ | (0.27 | ) | $ | (0.15 | ) | ||
| Weighted average common shares outstanding: | ||||||||
| Basic and diluted | 11,564 | 11,396 | ||||||
ProPhase Labs, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands)
| December 31 2019 | December 31 2018 | |||||||
| Cash and cash equivalents | $ | 434 | $ | 1,554 | ||||
| Marketable debt securites, available for sale | $ | 926 | $ | 6,687 | ||||
| Accounts receivable, net | $ | 2,010 | $ | 2,968 | ||||
| Inventory | $ | 1,459 | $ | 1,903 | ||||
| Total current assets | $ | 9,945 | $ | 18,238 | ||||
| Total assets | $ | 12,274 | $ | 20,737 | ||||
| Total current liabilities | $ | 933 | $ | 4,233 | ||||
| Total non-current liabilities | $ | 110 | $ | - | ||||
| Total stockholders' equity | $ | 11,231 | $ | 16,504 | ||||
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
